Sugi Predict

Sugi Predict / Compounds / SCHEMBL2498880

SCHEMBL2498880

SCHEMBL2498880

COC(=O)c1ccc(-c2cc(OC)ccc2F)c(C2=CC(C)(C)CC(C)(C)C2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ ABL1 P00519 2/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ ATM Q13315 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ IDH2 P48735 1/20 0.34
▸ BACE1 P56817 1/20 0.34
▸ FFAR1 O14842 3/20 0.34
▸ TP53 P04637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12221743 0.82 FFAR1 (0.39) FFAR1
SCHEMBL2498403 0.79 FFAR1 (0.37) FFAR1
SCHEMBL6068865 0.78 CA12 (0.38) CA1CA2KMT2AKDM4ESMN1; SMN2
SCHEMBL12192971 0.78 FFAR1 (0.37) IDH2FFAR1
SCHEMBL2500009 0.76 IDH1 (0.41) CA1CA2KMT2ACYP1A2CYP2D6
SCHEMBL2310188 0.75 SMN1; SMN2 (0.40) CA1CA2MAPK14KMT2ASMN1; SMN2
SCHEMBL1584527 0.75 FFAR1 (0.56) FFAR1
SCHEMBL2530396 0.75 SMN1; SMN2 (0.40) CA1CA2MAPK14KMT2ASMN1; SMN2
SCHEMBL2310183 0.75 SMN1; SMN2 (0.40) CA1CA2MAPK14KMT2ASMN1; SMN2
SCHEMBL2498048 0.75 CA1 (0.53) CA1CA2KMT2AKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 — — US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 — — US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 — — US disclosed
EP-2205548-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS Amgen, Inc (US) 2010-07-14 — — EP disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 — — US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 — — US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 — — US disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 CA1 4760/4885CA2 2000/4885ABL1 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.